This patent teaches that administration of "mega-dose" hematopoietic stem cell grafts may be useful for circuventing the requirement of completely ablating the recipient immune system. Use of this patent may allow for reduced neutropenic times and increased survival after bone marrow transplantation.
View this patent on the USPTO website.
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.